2.50
Hdl Handle:
http://hdl.handle.net/10033/346563
Title:
The impact of hepatitis E in the liver transplant setting.
Authors:
Behrendt, Patrick; Steinmann, Eike; Manns, Michael P; Wedemeyer, Heiner
Abstract:
Hepatitis E virus (HEV) infection has been identified as a cause of graft hepatitis in liver transplant recipients. The true frequency and clinical importance of HEV infections after liver transplantations is a matter of debate. It is proposed that consumption of HEV-contaminated undercooked meat is a main source for HEV infections in developed countries--which might also account for some hepatitis E cases after organ transplantation. However, HEV is also transmitted by transfusion of blood products, likely representing a previously underestimated risk particularly for patients in the transplant setting. HEV infection can take chronic courses in immunocompromised individuals, associated in some cases with rapid progression to cirrhosis within 1-2 years of infection. Diagnosis in transplanted patients is based on HEV RNA testing as antibody assays are not sensitive enough. Selection of immunosuppressive drugs is important as different compounds may influence viral replication and the course of liver disease. Ribavirin has antiviral activity against HEV and should be administered for at least three months in chronically infected individuals; however, treatment failure may occur. HEV infections have also been linked to a variety of extrahepatic manifestations both during and after resolution of infection. In this review we summarize the emerging data on hepatitis E with a particular focus on the importance of HEV infections for liver transplant recipients.
Citation:
The impact of hepatitis E in the liver transplant setting. 2014, 61 (6):1418-29 J. Hepatol.
Journal:
Journal of hepatology
Issue Date:
Dec-2014
URI:
http://hdl.handle.net/10033/346563
DOI:
10.1016/j.jhep.2014.08.047
PubMed ID:
25195557
Type:
Article
Language:
en
ISSN:
1600-0641
Appears in Collections:
publications of the research group virus transmission ([TC]VIRT)

Full metadata record

DC FieldValue Language
dc.contributor.authorBehrendt, Patricken
dc.contributor.authorSteinmann, Eikeen
dc.contributor.authorManns, Michael Pen
dc.contributor.authorWedemeyer, Heineren
dc.date.accessioned2015-03-12T15:28:20Zen
dc.date.available2015-03-12T15:28:20Zen
dc.date.issued2014-12en
dc.identifier.citationThe impact of hepatitis E in the liver transplant setting. 2014, 61 (6):1418-29 J. Hepatol.en
dc.identifier.issn1600-0641en
dc.identifier.pmid25195557en
dc.identifier.doi10.1016/j.jhep.2014.08.047en
dc.identifier.urihttp://hdl.handle.net/10033/346563en
dc.description.abstractHepatitis E virus (HEV) infection has been identified as a cause of graft hepatitis in liver transplant recipients. The true frequency and clinical importance of HEV infections after liver transplantations is a matter of debate. It is proposed that consumption of HEV-contaminated undercooked meat is a main source for HEV infections in developed countries--which might also account for some hepatitis E cases after organ transplantation. However, HEV is also transmitted by transfusion of blood products, likely representing a previously underestimated risk particularly for patients in the transplant setting. HEV infection can take chronic courses in immunocompromised individuals, associated in some cases with rapid progression to cirrhosis within 1-2 years of infection. Diagnosis in transplanted patients is based on HEV RNA testing as antibody assays are not sensitive enough. Selection of immunosuppressive drugs is important as different compounds may influence viral replication and the course of liver disease. Ribavirin has antiviral activity against HEV and should be administered for at least three months in chronically infected individuals; however, treatment failure may occur. HEV infections have also been linked to a variety of extrahepatic manifestations both during and after resolution of infection. In this review we summarize the emerging data on hepatitis E with a particular focus on the importance of HEV infections for liver transplant recipients.en
dc.language.isoenen
dc.titleThe impact of hepatitis E in the liver transplant setting.en
dc.typeArticleen
dc.identifier.journalJournal of hepatologyen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.